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Nonalcoholic fatty liver disease (NAFLD) is a multifactorial
disorder closely associated with the metabolic syndrome and
is the most common cause of abnormal liver function tests
(LFTs) in children. NAFLD is set to become the major cause of
liver transplantation in adults, and while it is rare for children
to develop end-stage liver disease from NAFLD, they may
become cirrhotic as adults. Understanding and managing
NAFLD in children may represent a method to intervene early
and alter the disease process. Furthermore, children with
steatosis require careful assessment as it may be secondary
to other conditions (e.g., Wilson’s disease [WD]). For these
reasons, pediatric NAFLD is of high importance to all gastro-
enterologists, hepatologists, and pediatricians.
NAFLD refers to a spectrum of diseases, ranging from
hepatic steatosis (“simple steatosis” or nonalcoholic fatty liver
[NAFL]) to nonalcoholic steatohepatitis (NASH) with or with-
out ﬁbrosis, to end-stage liver disease. Diagnosis requires
radiological (orhistological) demonstrationof steatosis, exclu-
sion of secondary causes, and no signiﬁcant alcohol intake.
Childrenpresent in threemainways: incidental abnormal LFT/
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Abstract Nonalcoholic steatohepatitis, a progressive form of nonalcoholic fatty liver disease
(NAFLD), is one of the most common hepatic diseases in children who present with
particular risk factors including obesity, sedentary lifestyle, and/or a predisposing genetic
background. The worldwide prevalence of NAFLD in children is a worrying phenomenon
because this disease is closely associated with the development of both cirrhosis and
cardiometabolic syndrome in adulthood. To date, the etiopathogenesis of primary NAFLD
in children is unknown. Understanding the pathogeneticmechanisms provides the basis to
characterize early predictors of the disease and noninvasive diagnostic tools and to design
novel speciﬁc treatments and possiblemanagement strategies. Despite a few clinical trials
on the use of antioxidants combined with lifestyle intervention for NAFLD, no treatment
exists for children with NAFLD. In this review, the authors provide an overview of current
concepts in epidemiology, histological features, etiopathogenesis, diagnosis, and treat-
ment of NAFLD in pediatric population.
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imaging, screening in obesity, and during investigation of
abdominal pain, the cause of which is not clear.
In this review, we aim to provide an overview of pediatric
NAFLD and discuss management in the context of recent
guidance.
Epidemiology
Paralleling the dramatic rise in pediatric obesity worldwide,
NAFLD has become a leading cause of chronic liver disease
during the developmental age, and the main determinant on
pediatric liver disease in Western countries.1 Several studies
have demonstrated a prevalence of 3 to 10% in general
pediatric populations, which increases up to 60 to 70% in
individuals with metabolic comorbidities.2 However, NAFLD
prevalence varies widely depending on geographical area
and diagnostic methods used.
Initial population-based studies, which estimated the pre-
valence of pediatric NAFLD by determining aminotransferases
or by ultrasonography in several countries, have indicated a
prevalence range of 3 to7%.1 In an autoptic study, conducted in
unselected children who died in accidents in California, the
prevalence of histological NAFLD ranged from 0.7% in 2- to
4-year-old to 17.3% in 15- to 19-year-old subjects, but increased
to 38% in obese children.3 In cohorts of children of various
nationalities selected for overweight or obesity, the prevalence
of elevated alanine aminotransferase (ALT) was higher and
ranged from 8 to 42%, whereas the prevalence of bright liver
ranged from 1.7 to 77%.4 A recent attempt to examine NAFLD
prevalence based on a meta-analysis of studies conducted in
76 different populations led to an estimate of 7.6% (95%
conﬁdence interval [CI]: 5.5–10.3%) in the general population
and 34.2% (95% CI: 27.8–41.2%) in obesity clinics.5 However,
there was a huge heterogeneity (I2 ¼ 98%), which was partly
accounted for by sex distribution , difference in bodymass index
(BMI), and ethnicity, with NAFLD prevalence being higher in
males, individuals with more severe adiposity, and Asians.
Importantly, use of liver enzymes instead of imaging to diag-
nose NAFLD led to a signiﬁcant underestimation of disease
prevalence.5
Indeed, obesity and metabolic syndrome features are the
major risk factors for pediatric NAFLD. The prevalence of this
condition is higher in overweight (gender- and age-speciﬁc
BMI > 85th percentile) or obese (>95th) children as com-
pared with normal weight pairs. However, due to the closest
link to insulin resistance, central adiposity, which is accumu-
lation of fat in visceral organs, plays a speciﬁc contribution in
determining disease risk.6,7 Indeed, waist circumference, an
easily available index of visceral fat, correlates with NAFLD
independently of BMI.1,8
Nutritional factors, such as excessive intake of calories,
processed food, and a sedentary lifestyle, play a key role in
the predisposition to liver fat accumulation, NAFLD, and
progressive liver disease.9,10 Fructose intake has emerged
as an important determinant of NAFLD risk, independently of
total caloric intake, probably due to the ability to stimulate
de novo lipogenesis (DNL).11,12 This has recently been
demonstrated to translate into increased risk of NASH.13
The quality of fat, and speciﬁcally a reduced omega-3:
omega-6 ratio, has also been reported to predispose to
NAFLD in children at higher risk.14 On the other hand, high
levels of physical activity are associatedwith protection from
NAFLD.8
Inherited factors account for a large proportion of the
interethnic and interindividual variability in the predisposi-
tion to NAFLD. Genetic studies have now identiﬁed the
speciﬁc common variants that inﬂuence hepatic fat meta-
bolism as important determinants of NAFLD in children and
adults.15–17 Also, in the developmental age, NAFLD is more
prevalent in individuals of Hispanic and Asian ethnicities as
compared with Europeans, whereas those of African ances-
try are relatively protected.5,18 The most validated genetic
risk factors are the PNPLA3 I148M and TM6SF2 E167K
mutations that inﬂuence lipid droplet remodeling and the
secretion of lipids from hepatocytes,19–21 GCKR P446L reg-
ulating lipogenesis,22 and genetic variation in the MBOAT7
gene that affects acyl chain remodeling of phosphatidylino-
sitol.17 Evaluation of these genetic risk variants increases the
ability to stratify the risk of NAFLD.23 Recent studies also
suggest a link between NAFLD and epigenetic modiﬁcations
and stable changes in expression of DNA related to chemical
modiﬁcations of DNA and chromatin structure, caused by
exposure to environmental factors.24 In fact, accumulating
evidence suggests that an adverse intrauterine environment
as detected by low birth weight is associated with increased
risk of pediatric and adult NAFLD.23,25
Histology
From a histopathological point of view, NAFLD encompasses
a disease spectrum ranging from “simple steatosis” (NAFL) to
NASH, which is characterized by the presence of hepatocel-
lular damage under the formof ballooning andmixed lobular
inﬂammation, is associated with the activation of pericellu-
lar–perisinusoidal ﬁbrogenesis, and evolves to ﬁbrosis, cir-
rhosis, and hepatocellular carcinoma (HCC) in a variable
proportion of cases.26 Other common features include Mal-
lory–Denk bodies, megamitochondria, acidophil bodies, and
iron accumulation.27
NASHisassociatedwith fasterprogressionof liverﬁbrosis as
comparedwith simple steatosis.28 Importantly,ﬁbrosis stage is
themain determinant of the prognosis of patientswith NAFLD,
concerning both liver-related and overall mortality.29–32
Pediatric NAFLD displays some peculiar histological fea-
tures compared with the adult form and, unlike the adult
disease, is rarely inﬂuenced by some secondary lifestyle
factors (e.g., alcohol and drugs), whereas others may have
a more prominent role (e.g., fructose intake). Indeed, two
different types of histological damagehave been described in
children with NAFLD:33 “type 1” NAFLD and “type 2” NAFLD.
Type 1 NAFLD refers to the histological features classically
associatedwith NASH in obese adults. These are represented
by steatosis, that is, accumulation of neutral lipids within
intracellular lipid droplets, which is generally more severe in
the centrilobular area. This is accompanied by hepatocellular
damage in the formof ballooning, lobular inﬂammation, and/
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or perisinusoidal ﬁbrosis. In contrast, type 2 NAFLD has been
described more frequently during the developmental age
and is characterized by steatosis with portal inﬂammation
and/or periportal ﬁbrosis. This form is more commonly
observed in males and in children of Hispanic or Asian
ethnicity as compared with Europeans.33 However, in the
majority of series, it was found that although type 2 features
are more frequent, most pediatric patients display overlap-
ping features of type 1 and type 2 NAFLD, which can be
considered the two extremes of a pathological spec-
trum.34–36 Importantly, portal inﬂammation, which is typi-
cal of type 2 NAFLD, has been associated with more severe
ﬁbrosis stage.37
In a recent series of 440 Caucasian children with histolo-
gical NAFLD, 12% had type 1, 22% had type 2, and 66% had
overlapping features.38 Remarkably, those with type 2 had a
more severe metabolic phenotype, with higher central adip-
osity and dyslipidemia. Furthermore, the presence of portal
inﬂammation, a feature of type 2 NAFLD, was independently
associated with waist circumference and clinically signiﬁ-
cant ﬁbrosis, suggesting that this histological feature is
involved in mediating faster progression of the disease.
Pathogenesis of Nonalcoholic Fatty Liver
Disease in Children
The pathogenesis of NAFLD in adults has been well-
deﬁned.39–42 In contrast, the pathogenesis of NAFLD in
children has not been the object of comparable attention,
and thus its contributing factors have yet to be mapped
comprehensively and fully understood. In the following
sections, we describe the key pre- and postnatal factors
that have been shown to affect the pathogenesis of NAFLD
in children.
Prenatal Factors
Recentevidencehasshownthat there aresomeprenatal factors
that are responsible for the pathogenesis of pediatric NAFLD,
such as maternal obesity, metabolic syndrome during preg-
nancy, gestational diabetes, and low birth weight.43–46 This is
supported by a series of well-conducted in vitro and in vivo
mechanistic studies. It is a multifactorial process that results
from a combination of biochemical factors (fetal insulin, lipid
proﬁle) and epigenetic modiﬁcation, which inﬂuences hepatic
DNL, mitochondrial function, and oxidative stress in hepato-
cytes, macrophages, and adipocytes.47–53 It is generally agreed
that a “secondhit” is required to initiate developmentofNAFLD
as an adolescent or adult, for which the most important is a
positive energy balance in the form of a high-fat/high-carbohy-
drate (Western) diet.46,51,52,54 Recent human studies showed
that there is an association between maternal prepregnancy
BMI and infant ectopic fat deposition in the liver and in the
intra-abdominal cavity45 (►Table 1). Magnetic resonance ima-
ging (MRI)hasbeenused tomeasureadiposityandhepatic liver
fat in newborns of obesemothers andwomenwith gestational
diabetes.44,45 In one of these studies, a correlation was shown
between gestational BMI and offspring hepatic lipid accumula-
tion.45Though it isunclearwhether thesesamenewbornsgoon
to develop progressive NAFLD, a possible explanation for the
ectopic hepatic fat deposition in these newborns may be that
immature fetal adipocytes are not sufﬁciently developed to
accommodate and store lipids crossing the placenta in excess,
throughout pregnancy. Consequently, in thepresence ofmater-
nal obesity or gestational diabetes mellitus (two states where
nonesteriﬁed fattyacid concentrationsmightbeexpected to be
increased), excess transference of maternal lipid will result in
accumulation of fetal ectopic fat as the fetus is not able to
expand adipose depots to buffer the increased transplacental
lipid delivery.55 The presence and persistence of liver fat after
birth have also been shown by us in amousemodel developed
to investigate developmental programming of offspring
NAFLD.56 In this study, we showed that increased dietary
maternal fat intake in the mother from before conception
primed the development of increased liver fat in the offspring
mice in adulthood, even if the offspring mice had only ever
eaten a normal chow (carbohydrate-rich, low-fat) diet from
weaning until adulthood. Furthermore, adult mice that had
been exposed in utero to increased dietary maternal fat intake
in the mother from before conception, coupled with only
consuming the same high-fat diet from weaning until adult-
hood, developed a ﬂorid form of NASH, which was a consider-
ably more severe form of NAFLD than comparator mice who
had only been exposed to the high-fat diet fromweaning until
adulthood. Additionally, mice exposed to gestational high-fat
diet had decreased mitochondrial electron transport chain
function, suggesting that a stressor in early live causeddysfunc-
tional mitochondria that are less efﬁcient at preforming mito-
chondrial β-oxidation, predisposing the mouse to hepatic fat
accumulation and programming the development of NAFLD in
adulthood. Another interesting prenatal factor associatedwith
the pathogenesis of pediatric NAFLD is the perturbation of
intrauterine environment during pregnancy. According to the
“thrifty phenotype” hypothesis, intrauterine growth retarda-
tion can lead to several chronic conditions and metabolic
disorders (such as NAFLD) later in life.57 We have shown that
the “small for gestational age” statewassigniﬁcantlyassociated
with severe liver steatosis (NAFLDActivity Score > 5) in child-
hood.58 Moreover, in a large epidemiological study, Sandboge
et a have also shown that bodyweight at 2 yearswas negatively
associated with NAFLD after adjusting for age, sex, and gesta-
tional age. Thus, the current evidence to date suggests that the
intrauterine environment has the potential to have a powerful
effect on the offspring’s future riskofdevelopingNAFLD later in
life.
Postnatal Factors
The postnatal factors predisposing to pediatric NAFLD are
similar to those for adult NAFLD and include common factors
such as obesity, hyperinsulinemia, and insulin resistance. In
the presence of obesity, the potential for good adipose tissue
expansion is fundamental for maintaining lipid homeostasis
and insulin sensitivity and for protecting the lipid from
increased lipid and inﬂammatory ﬂuxes that have the poten-
tial for promoting development and subsequent progression
of NAFLD. When the process of the adipose tissue expan-
sion fails, there is an associated low-grade inﬂammation
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associated with adipocyte autophagy and adipokine produc-
tion. In this low-grade inﬂammatory state, there is increased
ﬂux of free fatty acids from the adipose tissue to the liver
together with increased proinﬂammatory cytokines causing
the recruitment of macrophages in adipose tissue, stimulat-
ing the production of TNF-α, IL-6, and reactive oxygen
species, and increasing adipocyte lipolysis.59 In the liver,
the combined effect of free fatty acids and adipokines coming
from the adipose tissue increases endoplasmic reticulum
stress with consequent activation of Kupffer cells, and this
triggers liver inﬂammation, potentially promoting develop-
ment of NASH.60 This inﬂammatory state triggers a cascade
of hepatocyte injury and increases oxidative stress and
mitochondrial dysfunction with consequent impairment of
liver metabolic capacity. Hyperinsulinemia and insulin resis-
tance also contribute to the development of NAFLD in
adolescence as during puberty, children experience a phy-
siological state of insulin resistance. In a large cross-sectional
study, Moran et al studied 357 healthy children and adoles-
centswho underwent hyperinsulinemic–euglycemic clamps.
They showed that there are signiﬁcant differences in insulin
resistance between boys and girls and that insulin resistance
increases signiﬁcantly at Tanner stages 2, 3, and 4 but
decreases to near prepubertal levels at Tanner stage 5.
Furthermore, while insulin resistance was related to BMI
and anthropometric measures of fatness, these factors did
not completely explain the insulin resistance that occurs
during the Tanner stages of puberty.61 Moreover, in further
work, the authors showed there are sex-related develop-
mental changes in insulin resistance, which are independent
of changes in adiposity.62 During the transition from late
childhood through adolescence, insulin resistance in males
increased in association with increased triglyceride concen-
trations and decreased high-density lipoprotein cholesterol
levels. This phenomenon was noted despite a concurrent
reduction in body fatness in male children, whereas the
opposite effect was observed in female children. It is inter-
esting to speculate that these sex-related developmental
changes in insulin resistance may underpin not only differ-
ences in NAFLD prevalence between males and females in
adulthood but also differences in cardiovascular risk
between males and females in adult life.
In childhood, a physiological state of insulin resistance
plus a sedentary lifestyle and the consumption of unhealthy
food63may increase obesity, decrease skeletal muscle oxida-
tion of lipids, and promote hepatic DNL. In the presence of
hyperinsulinemia that is associated with insulin resistance,
acetyl-CoA carboxylase is activated by insulin, and acetyl-
Table 1 Human evidence for prenatal and infant risk factors associated with NAFLD
Study Methodology Findings
Ayonrinde et al123 N ¼ 1,170
Mean age: 17 y
Prospective
USS-diagnosed NAFLD
NAFLD independently associated with:
Maternal prepregnancy obesity
(OR: 2.3)
Breastfeeding 64 mo (OR: 0.6)
Adolescent obesity (OR: 9.1)
Bugianesi et al;58 Nobili et al;124 and
Nobili et al25
N ¼ 288
Mean age: 13 y
Retrospective
Biopsy-diagnosed NAFLD
Low birth weight associated with
increased severe steatosis and portal
inﬂammation, independent of insulin
resistance
Each month of breastfeeding reduced
NASH (OR: 0.7) and ﬁbrosis (OR: 0.9)
SGA associated with insulin resistance
Suomela et al23 N ¼ 2,042
Mean age: 42 y
Prospective
USS-diagnosed NAFLD
NAFLD independently associated with:
Preterm birth (OR: 2.4)
Small for gestation age (OR: 1.8)
Birth weight (OR: 0.8)
Insulin at 11 y (OR: 1.3)
Breij et al125 N ¼ 268
Mean age: 21 y
Retrospective
FLI-diagnosed NAFLD
Rapid catch-up growth in the ﬁrst 3 mo
associated with high FLI score
No association of FLI with SGA
Sandboge et al126 N ¼ 1,587
Mean age: 62 y Retrospective
NAFLD liver fat score/equation diag-
nosed NAFLD
Weight at 2 y negatively correlated with
NAFLD score
Low weight at 2 y with later adult obe-
sity had high risk of NAFLD (OR: 19.5)
Fraser et al127 N ¼ 2,101
Mean age: 68 y
Retrospective
Abnormal LFT
Birth weight negatively correlated with
ALT, GGT, and ALP
Abbreviations: ALT, alanine aminotransferase; AST; aspartate aminotransferase; FLI, fatty liver index; GGT, gamma–glutamyl transpeptidase; LFT,
liver function test; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; OR, odds ratio; SGA, small for gestational age; USS,
ultrasound scan.
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CoA is converted into malonyl-CoA, which is the committed
step in hepatic fatty acid synthesis. There are two important
transcription factors that regulate DNL: sterol regulatory
element-binding protein-1 (SREBP-1c) and carbohydrate
response element-binding protein (ChREBP). These tran-
scription factors regulate enzymes involved in fatty acid
and triacyl glycerol synthesis. In addition, a high-carbohy-
drate diet, particularly one that contains high levels of diet-
ary fructose, can increase hepatic DNL by increasing
substrate supply and promoting the expression of SREBP-
1c and ChREBP.64,65 DNL is an energy-expensive process
consuming 7 ATPs and 14 NADPH to generate each palmitate
from acetyl-CoA.66 Consistent with this, fructose causes
hepatic ATP depletion with resultant oxidative stress and
potential for mitochondrial dysfunction.67,68
Softic et al investigated the differential effects of glucose
and fructose in a mouse model and showed that the addition
of fructose to a high-fat diet was associated with increased
expression of SREBP-1c and ChREBP and increased fatty acid
synthesis, as well as hepatic insulin resistance. In contrast,
when glucose was added to the high-fat diet, the authors
found an increase in total ChREBP and liver triglyceride
accumulation but not insulin resistance (►Fig. 1).64,69 In
the same study, Softic et al studied hepatic expression of
ketohexokinase (KHK), an enzyme that catalyzes the ﬁrst
step of intracellular fructose metabolism,70 in bothmice and
obese adolescents with NAFLD who were undergoing bar-
iatric surgery. The authors found that KHK expression was
increased twofold in mice whose high-fat diet was supple-
mented with fructose. This ﬁnding contrasted with their
observations in mice whose high-fat diet was supplemented
with glucose, where KHK expression did not increase sig-
niﬁcantly. In the adolescents, KHK expression was twofold
higher in obese patients with NASH compared with obese
patients without fatty liver. Thus, these data suggest that
dietary fructose is associatedwith an increased expression of
KHK favoring the production of acyl-CoA that contributes to
the development of NAFLD through increased DNL.69 The
high activity of KHK contributes to reduced cellular ATP by
rapid phosphorylation of fructose, and, through regeneration
of ATP in oxidative phosphorylation, hepatocytes become
depleted in inorganic phosphate. The net effect is elevated
uric acid71 production, which has been independently asso-
ciated with advanced NASH histology in children.13
Hepatic Outcomes
The long-term hepatic outcomes of pediatric NAFLD are not
clear due to a lack of prospective natural history data, and few
children undergo paired biopsies. The outcomes of NAFLD in
adults are more deﬁned, where data demonstrate that after
over 30 years of follow-up, NAFLD is associatedwith increased
all-cause mortality (hazard ratio [HR]: 1.3) and HCC in (OR:
6.6).30 Overall, liver-related events occur in < 10% of patients
with NAFLD, but there is a strong correlation with ﬁbrosis
stage and outcome.29 In addition, it has been suggested that
Fig. 1 Pre- and postnatal factors contribute in NAFLD pathogenesis.
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there is agroupof “rapidprogressors”whomaydevelop severe
ﬁbrosis within 5 years,28 though it remains to be established
whether this is due to sampling variability on repeat biopsy.
Liver-related causes of death are third after cardiovascular
disease and nonhepatic malignancy.
There are no robust data to determine whether this
natural history holds true for pediatric NAFLD. It is also
not well establishedwhat proportion of childrenwith NAFLD
continue to have NAFLD as adults. It is known that around a
third of obese adolescents will become obese adults,72 but a
follow-up study from pediatric to adult transition in NAFLD
has not yet been reported.
Feldsteinet al reporteda retrospective cohortof 66children
with NAFLD in which 2 children underwent transplant for
decompensated cirrhosis.73 This study has the longest follow-
up, but its retrospective design and lack of data on method of
diagnosis for children limit its conclusions. There have been
other case series to suggest that severe ﬁbrosis is possible
while still a child;74however, it is generally regarded that end-
stage liver disease while under 16 years of age is unlikely to
be secondary to NAFLD alone and should prompt a search for
alternative diagnoses.75 It is worthy to mention that there are
some speciﬁc circumstances, particularly acquired hypotha-
lamic–pituitary insufﬁciency, that may be associated with
rapid progression of ﬁbrosis.76
In adults, ﬁbrosis is the sole predictor of long-term liver-
related events.31 This ﬁnding has been reproduced in multi-
ple cohorts, and noninvasive ﬁbrosis scores (NAFLD ﬁbrosis
score, Fibrosis 4, BARD [BMI 28 kg/m2, an AST/ALT ratio
0.8 and diabetes]) correlatewithmortality.77While similar
scores exist in pediatric NAFLD (e.g., the pediatric NAFLD
ﬁbrosis index78), it is not knownwhether they correlatewith
long-term outcome.
Data from randomized controlled trials demonstrate that
stage 1 and2ﬁbroses are readily reversiblewithin 2 years.79,80
It is not known towhat extent advanced ﬁbrosis can regress in
pediatric NAFLD.
Therefore, to accurately determine the long-term hepatic
outcomes in pediatric NAFLD, natural history studies are
required. These have recently been established on both sides
of the Atlantic81,82 and are likely to require more than
20 years follow-up to quantify rates of HCC development
and liver failure.
Dangerous Liaisons
There are several potential pitfalls in the diagnosis, monitor-
ing, and management of pediatric NAFLD, which will be
discussed in this section.
The most important point about diagnosing NAFLD in chil-
dren is to exclude conditions masquerading as fatty liver. It is
recognized that a variety of liver and systemic disorders may
cause secondary steatosis, including those listed in ►Table 2.
Schwimmer et al presented strong evidence for liver biopsy
in childrenwith suspectedNAFLD.Outof 374children referred
from primary care, 255 underwent biopsy and 61 had a
diagnosis other than NAFLD, most frequently autoimmune
hepatitis. Children and adults with “lean” NAFLD, with BMI
and waist circumference < 95 percentile, are more likely to
have secondary causes for steatosis or NAFLD-associated
polymorphisms.83 In very lean children with severe insulin
resistance, lipodystrophy should be considered.84
Differentiating between WD and NAFLD may be very
challenging, and some pediatricians would argue that biopsy
is the only method to truly exclude WD. Ceruloplasmin is a
good screening test for WD and, depending on the threshold
used, may have a negative predictive value of 99%
(►Table 3).85However, a subset of patients may have normal
ceruloplasmin, and missing the diagnosis can result in
permanent neurologic damage. Therefore, a liver biopsy
with dry weight copper improves the reliability of diagnosis,
but can give a false-positive result (for WD) as cholestatic
disorders can cause copper accumulation.75 Molecular
genetics can be used to make a diagnosis of WD, but ATP7B
can be affected by a variety of mutations; therefore, genetics
cannot exclude the diagnosis.86
Lysosomal acid lipase deﬁciency (LAL-D), also known as
cholesterol ester storage disease, is a potential differential
Table 2 Some secondary causes of hepatic steatosis that should be excluded before making a diagnosis of pediatric NAFLD
Secondary causes of NAFLD Test Abnormality
Hepatitis B and C, EBV, CMV Viral hepatitis serology IgG or IgM serology positive
Wilson’s disease Serum ceruloplasmin Low levels
Liver biopsy Raised dry weight copper
Autoimmune hepatitis Autoantibodies Positive ANA/ASMA
Immunoglobulins Increased IgG
Alpha-1-antitrypsin deﬁciency Alpha-1-antitrypsin levels and Pi type PiZZ
Hereditary hemochromatosis Serum iron studies Raised ferritin and transferrin saturation
Lipodystrophy and other insulin-resis-
tance syndromes
Clinical examination Reduced subcutaneous adipose
Serum fasting insulin Greatly elevated
LAL deﬁciency Dry blood spot assay Reduced LAL activity
Abbreviations: ANA, antinuclear antibodies; ASMA, antismooth muscle antibodies; CMV, cytomegalovirus; EBV, Epstein–Barr virus; IgG,
immunoglobulin G; IgM, immunoglobulin M; LAL, lysosomal acid lipase; NAFLD, nonalcoholic fatty liver disease.
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diagnosis for NAFLD. This rare, autosomal recessive lysoso-
mal disorder has a wide spectrum of clinical presentation.87
Wolman disease is the most severe form, with rapidly
progressive liver failure in infants. A milder form presents
in childhood or adults with hepatic steatosis, raised amino-
transferases, raised low-density lipoprotein, and low high-
density lipoprotein. Diagnosis is theoretically important
because of the potential for treatment with sebelipase
alfa.88 However, despite the possibility of misdiagnosis of
LAL-D as NAFLD, or a role of LAL in NAFLD,89 to date there are
no reports of identiﬁcation of LAL-D in cohorts of children
with fatty liver; therefore, its relevance to routine clinical
practice remains to be established.
It is not clear how best to monitor pediatric NAFLD, but it
is well established that aminotransferases are a poor marker
of disease activity. Alanine aminotransferase (ALT) and
aspartate aminotransferase ﬂuctuate throughout the disease
course and do not correlate with ﬁbrosis,90 though they may
show some correlation with NAFLD activity score.38 Blood
often becomes most abnormal during the relatively insulin-
resistant state of adolescence;91 therefore, a reduction of ALT
without evidence of weight loss should not be relied upon as
a reassuring ﬁnding.
Though the long-term cardiovascular and metabolic out-
comes of pediatric NAFLD have yet to be formally quantiﬁed,
these are likely to be the main burden of disease for patients
in adult life.29,32 Therefore, hepatologists must remember
that weight loss and improvement of insulin resistance are
the most important management goals. Apart from thera-
pies, targets at improving liver disease activity are discussed
below.
Management Program
The treatment of pediatric NAFLD can be divided into con-
servative, medical, and surgical approaches. As alluded to
above, the determinants of successful management are not
clear as the natural history of the condition is uncertain. The
goals are multidimensional: improve themetabolic health of
children to reduce their long-term cardiovascular risk and
reduce liver-related clinical events, presumably by targeting
ﬁbrosis. Results from the major controlled trials in pediatric
NAFLD are summarized in ►Table 4.
Weight loss is the core therapy for pediatric NAFLD and for
all children with obesity.92 This may be achieved by dietary
modiﬁcation and/or physical activity. A variety of diets have
been used in randomized and nonrandomized clinical trials.
The most frequently used diet is a “low-fat” hypocaloric diet
with 25 to 30 kcal/kg, 50 to 60% carbohydrate and 23 to 30%
fat (with one-third saturated fat).80,93,94 A recent systematic
review of dietary and physical activity interventions found
that there was insufﬁcient evidence to suggest any single
method of weight loss, but that greater weight loss gave a
larger improvement in noninvasive markers of NAFLD.95 In
studies with biopsy endpoints, a reduction in age- and sex-
corrected BMI is associatedwith an improvement in features
of NAS and ﬁbrosis.80
There is recent physiological evidence to suggest that
fructose restriction improves the metabolic proﬁle of obese
children and potential for treatment of fatty liver.12 Low-
carbohydrate96 or low-fructose97 diet has only been used in
pilot studies on pediatric NAFLD; however, there are several
larger studies planned.98
However, it must be remembered that even with close
follow-up in well-conducted clinical trials, there is a rela-
tively poor response to dietary and physical activity in
childhood obesity.99 Compliance is poor, and participants
with low uptake of advice have greater increases in amino-
transferases.93 Therefore, NAFLD should ideally be managed
in a multidisciplinary clinic that includes a dietician, clinical
nurse specialist, and clinical psychologist to give the best
chance of achieving weight loss.
There are no approved pharmacological therapies of
pediatric NAFLD.100 The main groups of agents that have
been tested to date are antioxidants, metformin, polyunsa-
turated fatty acids (PUFAs), probiotics, and vitamin D.
The American Association for the Study of Liver Diseases
(AASLD) guidance recommends vitamin E as the only therapy
that is potentially efﬁcacious in pediatric NAFLD.92 This is
primarily based on data from the Treatment of NAFLD in
Children (TONIC) trial that demonstrated an improvement in
ballooning and overall NAS with vitamin E use, without any
major adverse events.79 Other studies have used vitamin E in
a variety of doses and durations but have been limited by not
using protocolled paired biopsies,93,101 combination treat-
ment,80,102 or differing weight loss between intervention
arms.103Overall, vitamin E is probably safe andmay improve
NASH activity, though it remains to be established if this
translates into improved liver-related outcomes.
Results from a randomized trial of cysteamine bitartrate
delayed release (CBDR) have recently shown modest
improvements in lobular inﬂammation, and there was over-
all improvement in histology in participants weighing under
65 kg.104 It acts by increasing intracellular glutathione,
Table 3 Data on the validity of use of three different cutoff thresholds of ceruloplasmin for the diagnosis of Wilson’s disease in
patients clinically suspected of having the condition
Ceruloplasmin
concentration
cutoff (g/L)
Sensitivity (%) Specificity (%) Positive predictive
value (%)
Negative predictive
value (%)
0.20 98 56 48 99
0.14 93 100 100 97
0.10 79 100 100 92
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Table 4 Randomized controlled trials in pediatric NAFLD
Trial N Intervention End points
Dietary intervention
Vos et al97 10 Low-fructose vs. low-fat diet Liver enzymes: no effect
Ramon-Krauel
et al96
16 Low-glycemic-load vs. low-fat diet Liver enzymes and MRS: improved but no dif-
ference between groups
Jin et al128 21 Low-fructose vs. standard diet Liver enzymes and MRS: no effect
Antioxidants
Vajro et al93 28 Lifestyle vs. lifestyle þ vitamin E Liver enzymes: improved but no difference
between groups
US: unchanged
Nobili et al80 53 Lifestyle vs. lifestyle þ vitamin E þ vitamin C Histological steatosis, lobular inﬂammation,
ballooning, and NAS: improved but no differ-
ence between groups
Wang et al103 76 No intervention vs. strict lifestyle vs. unstruc-
tured lifestyle þ vitamin E.
Liver enzymes: improved with strict lifestyle
intervention
US: unchanged
Lavine et al79 173 Metformin vs. vitamin E vs. placebo NAS and ballooning improved with vitamin E
Liver enzymes: improved but no difference
between groups
Akcam et al101 67 Lifestyle vs. lifestyle þ metformin vs. lifestyle
þ vitamin E
Liver enzymes: improved but no difference
between groups
Shiasi Arani et al105 119 Metformin vs. vitamin E vs. placebo US: improved but no difference between drugs
Schwimmer et al104 169 CBDR vs. placebo Lobular inﬂammation: improved
Liver enzymes: improved
Zöhrer et al102 40 Lifestyle vs. lifestyle þ DHA-Cho-VE Liver enzymes and US: improvedwith DHA-Cho-VE
Histological improvement in DHA-Cho-VE, but no
biopsy in placebo for comparison
Metformin
Nadeau et al106 50 Lifestyle vs. lifestyle þ metformin Liver enzymes: improved but no difference
between groups
US: improved with metformin
Polyunsaturated fatty acids
Nobili et al108 60 DHA vs. placebo Liver enzymes and US steatosis: improved
Boyraz et al94 108 Lifestyle vs. lifestyle þ PUFA Liver enzymes and US: improved in lifestyle þ
PUFA group
Janczyk et al129 76 DHA/EPA vs. placebo Liver enzymes and US: improved but no differ-
ence between groups
Paciﬁco et al109 51 DHA vs. placebo Liver enzymes: improved but no difference
between groups
MRI hepatic fat: improved
Della Corte, et al117 41 DHA þ vitamin D vs. placebo Liver enzymes: improved
Histological improvement in DHA þ Vitamin D,
but no biopsy in placebo for comparison
Probiotics
Vajro et al130 20 Lactobacillus vs. placebo Liver enzymes: improved
US: unchanged
Alisi et al110 44 Lifestyle vs. lifestyle þ VSL#3 Liver enzymes: unchanged
US: improved with VSL#3
Famouri et al111 64 Prokid probiotic vs. placebo Liver enzymes and US steatosis: improved
Bariatric surgery
Manco et al118 93 Sleeve gastrectomy vs. IGWLD vs. lifestyle
(nonrandomized)
Fibrosis and NASH: improved most in sleeve
gastrectomy as well as in IGWLD
Abbreviations: CBDR, cysteamine bitartrate delayed release; DHA, docosahexaenoic acid; DHA-Cho-VE, docosahexaenoic acid with choline and
vitamin E; EPA, eicosapentaenoic acid; IGWLD, intragastric weight loss device; MRS, magnetic resonance spectroscopy; NAFLD, nonalcoholic fatty
liver disease; NAS, NAFLD activity score; NASH, nonalcoholic steatohepatitis; PUFA, polyunsaturated fatty acids; US, ultrasound; VSL#3, a probiotic
mixture.
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which then scavenges oxygen free radicals. The evidence
body for CBDR is smaller than that for vitamin E, and it is
likely that further studies will be required before it is
incorporated into guidelines.
Metforminhashadmoremodest results,with some reports
of improved radiological evidence of steatosis,105,106 but
randomizedbiopsydata are limited than those fromtheTONIC
trial.79However, aside from its effects on the liver, metformin
may be used by pediatric endocrinologists in children with
insulin resistance and thus at a risk of type 2 diabetes.99,107 At
this time, consensus guidelines do not recommendmetformin
as a primary treatment for NAFLD or NASH.
PUFAs, mostly docosahexaenoic acid (DHA) and eicosa-
pentaenoic acid, are given with the aim of alerting the
composition of the hepatic lipidome and reducing lipotoxi-
city. Noninvasive data are encouraging, where use of at least
250 mg per day for 6 months may result in reduction of
radiological steatosis, but there are no biopsy data available
to conﬁrm these ﬁndings.94,108,109
The evidence of use of probiotics is similar: a variety of
regimens have been used in trials for pediatric NAFLD, but
there are no studies with biopsy endpoints to date.110,111
Although there is a large body of evidence that conﬁrms the
association of intestinal dysbiosis with obesity and
NAFLD,112–114 there are little data to support modulation
of the microbiome as a primary treatment strategy.
The association of vitamin D deﬁciency with pediatric
obesity,115 NAFLD, and NASH116 is relatively well estab-
lished, and the use of replacement therapy in deﬁcient
children is logical. Indeed, in children deﬁcient in vitamin
D, replacement in combination with DHA does improve
histology.117 However, it remains to be demonstrated
whether children with acceptable 25-OH-D3 (>20 ng/L)
beneﬁt from supplementary vitamin D. In addition, the
risk of hypervitaminosis and resulting renal impairment
must be considered.
Finally, bariatric surgery is a treatment option for severe
pediatric obesity with comorbidities. Expert consensus
recommends that NAFLD should not be a primary indication
for weight loss surgery; however, evidence does suggest it to
be of use, with potential for reversal of ﬁbrosis.118,119 These
ﬁndings are consistent with data from adults, though there
were insufﬁcient unbiased studies for a Cochrane review to
recommend it as a primary treatment.120However, the long-
term data are clear that bariatric surgery improves the
metabolic and cardiovascular outcomes for obese indivi-
duals,121 and therefore it may be part of the care for patients
with NAFLD. The psychological effects of bariatric surgery
are not to be underestimated, and there are emergingdata on
the impact that such operations have on patients later in
adult life.122
Therefore, weight loss is the primary treatment of pedia-
tric NAFLD, and it appears that the method by which this is
achieved does not affect the outcome. Vitamin E is the only
drug treatment that may be a direct hepatic beneﬁt, but
pharmacological management of the liver is a small compo-
nent of the overall care for children with the metabolic
syndrome.
Implications and Future Directions
The implications of these data are that pediatric NAFLD is
increasing, and that these patients will become adults with
end-stage liver disease or HCC in 10 to 30 years’ time. Weight
loss is the only intervention demonstrated to have signiﬁcant
efﬁcacy. Further investigation into the pathogenesis of pedia-
tric NAFLD is needed to complement translational studies,
with an aim to develop novel therapeutic strategies. There are
onlya fewagents in trials in children, and drug development is
progressing at a much slower rate than in adults.
Futuredirectionsmust focusonestablishing andexpanding
our understanding ofNAFLDpathogenesiswith a translational
therapy in mind, for example, determining the microbiome
phylogeny associated with less severe ﬁbrosis and trialing
probiotic therapy. It may also involve exploring whether
recent advances in adult hepatology are also applicable to
pediatrics, suchas the roleofVAP-1 ingut–liver axis,whichhas
not yet been investigated in children. There is much hetero-
geneity in investigationsofNAFLD,particularly in regard to the
use of biopsy, and establishing biomarkers that correlate with
histology progression and clinical outcomes remains a major
target. Finally, despiteweight lossbeing theprimary treatment
for NAFLD, minimal progress has been made in guidance on
determining the optimal regimen of lifestyle changes.
In conclusion, despite major advances in understanding,
research in pediatric NAFLD has not yet translated into
patient beneﬁt. It is an important condition with unmet
scientiﬁc and clinical needs that requires urgent attention to
slow the future epidemic of end-stage liver disease in adults.
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